The incretin hormone glucagon‐like peptide‐1 (GLP‐1) is released from enteroendocrine L‐cells in the intestine,1 from where it binds cognate receptors to promote the survival of pancreatic beta cells, insulin release, and weight loss.2 For these reasons, incretin mimetics based on GLP‐1 have become widely‐prescribed drugs for the restoration of normal glucose levels in type 2 diabetes (T2D),3 a socioeconomically costly syndrome affecting almost 400 million individuals worldwide.4 Here, GCG is linked to type 2 diabetes mellitus.